scholarly journals Selection of drug resistant mutants from random library of Plasmodium falciparum dihydrofolate reductase in Plasmodium berghei model

2011 ◽  
Vol 10 (1) ◽  
pp. 119 ◽  
Author(s):  
Wachiraporn Tipsuwan ◽  
Somdet Srichairatanakool ◽  
Sumalee Kamchonwongpaisan ◽  
Yongyuth Yuthavong ◽  
Chairat Uthaipibull
1995 ◽  
Vol 39 (4) ◽  
pp. 948-952 ◽  
Author(s):  
P A Winstanley ◽  
E K Mberu ◽  
I S Szwandt ◽  
A M Breckenridge ◽  
W M Watkins

The potency of antimalarial dihydrofolate reductase inhibitors, alone and in synergistic combination with dihydropteroate synthetase inhibitors, against the Kenyan K39 strain of Plasmodium falciparum (pyrimethamine resistant) and against normal replicating human bone marrow cells in in vitro culture has been studied. Therapeutic indices and rank order of synergistic potency were derived. Trimethoprim, pyrimethamine, and the quinazolines WR159412 and WR158122 had the smallest therapeutic indices (1.39, 4.38, 2.56, and 90.0, respectively), while the three triazines clociguanil, WR99210, and chlorcycloguanil had the largest (3,562, 3,000, and 2,000, respectively). In rank order of decreasing activity against P. falciparum, the six most potent drug combinations were WR99210-dapsone, chlorcycloguanil-dapsone, WR158122-dapsone, WR159412-dapsone, WR159412-sulfamethoxazole, and chlorcycloguanil-sulfamethoxazole; pyrimethamine-sulfadoxine was the least potent combination. These experiments form a basis for the selection of rapidly eliminated antifolate combinations for further clinical testing.


2007 ◽  
Vol 79 (13) ◽  
pp. 5006-5012 ◽  
Author(s):  
Chawanee Thongpanchang ◽  
Supannee Taweechai ◽  
Sumalee Kamchonwongpaisan ◽  
Yongyuth Yuthavong ◽  
Yodhathai Thebtaranonth

Sign in / Sign up

Export Citation Format

Share Document